Press Releases

All Releases
AngioDynamics to Report Fiscal 2019 First Quarter Financial Results on September 27, 2018
Sep 13, 2018

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 13, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of

AngioDynamics to Acquire RadiaDyne and its Revolutionary OARtrac® Radiation Dose Monitoring Platform to Further Expand Oncology Portfolio
Sep 13, 2018

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 13, 2018-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced an agreement to acquire RadiaDyne, a privately held medical

AngioDynamics to Present at Two Investor Conferences in September
Aug 23, 2018

LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 23, 2018-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that it will present at the following two investor conferences in

AngioDynamics Provides Updates on Oncology and Vascular Access Businesses
Aug 15, 2018

LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 15, 2018-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today provided a corporate update on enhancements made to its Oncology business and

AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results
Jul 11, 2018

Fiscal 2018 Fourth Quarter Highlights Net sales of $88.3 million , an increase of 1.6% year over year Gross margin expanded 500 basis points year over year to 53.7% GAAP EPS of $0.06 per share; adjusted EPS of $0.20 per share Operating cash flow of $23.8 million ; free cash flow of $23.0 million

AngioDynamics to Report Fiscal 2018 Fourth Quarter and Full-Year Financial Results on July 11, 2018
Jun 21, 2018

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 21, 2018-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the fourth

AngioDynamics to Present at Two Investor Conferences in May
Apr 10, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will present at the following two investor conferences in May:
AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results
Mar 29, 2018
Fiscal 2018 Third Quarter Highlights Net sales of $83.9 million , a decrease of 2.0% year over year Gross margin expanded 300 basis points year over year to 54.2% GAAP EPS of $0.37 ; Adjusted EPS of $0.25 per share Announced the launch of a wireless ultrasound device FDA granted Breakthrough
AngioDynamics to Present at the Needham 17th Annual Healthcare Conference
Mar 15, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial
AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March 29, 2018
Feb 27, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the third quarter of fiscal
AngioDynamics to Present at the Barclays Global Healthcare Conference
Feb 15, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and Michael C.
AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife® System for the Treatment of Stage III Pancreatic Cancer
Jan 24, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration (FDA) has granted
AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results
Jan 04, 2018
Fiscal 2018 Second Quarter Highlights Net sales of $86.7 million , a decrease of 2.6% year over year U.S. GAAP EPS of $0.01 ; Adjusted EPS of $0.16 per share Operating cash flow of $10.2 million ; free cash flow of $9.4 million LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
Dec 19, 2017
LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 19, 2017-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Jim Clemmer , President and Chief Executive Officer,
AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on January 4, 2018
Dec 11, 2017
LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 11, 2017-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report financial results for the second
AngioDynamics Reports Fiscal 2018 First Quarter Results
Sep 28, 2017
Q1 net sales of $85.4 million , down 3% year-over-year              Q1 GAAP earnings per share of $0.00 ; adjusted EPS of $0.12 Q1 operating cash generation of $3.0 million ; free cash flow generation of $2.5 million Company reaffirms fiscal 2018 guidance ALBANY, N.Y. , Sept.
Outcomes in a Nurse-Led Peripherally Inserted Central Catheter Program: A Retrospective Cohort Study Published in CMAJ Open
Sep 14, 2017
Low rates of major PICC-associated complications attributed in-part to the novel BioFlo catheter material Data to be presented at AngioDynamics -sponsored symposium at the annual scientific meeting of the Association for Vascular Access ALBANY, N.Y. , Sept.
AngioDynamics to Report Fiscal 2018 First Quarter Financial Results
Sep 14, 2017
ALBANY, N.Y. , Sept. 14, 2017 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2018 first
AngioDynamics to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
Sep 13, 2017
ALBANY, N.Y. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Michael C.
AngioDynamics to Present at the 2017 Morgan Stanley Global Healthcare Conference
Aug 29, 2017
ALBANY, N.Y. , Aug. 29, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer and
Displaying 1 - 20 of 621

Copyright Nasdaq. Minimum 15 minutes delayed.